Advanced searches left 3/3

Cell Activity Multiple Myeloma - Europe PMC

Summarized by Plex Scholar
Last Updated: 23 January 2022

* If you want to update the article please login/register

A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.

In vitro and ex vivo, we intend to investigate VP79s' function and related mechanisms of action in several myeloma cells. In a panel of drug-sensitive and drug-resistant MM cell lines, as well as ex vivo patient samples and normal donor lymphocytes and platelets, the effects of VP79s on cell viability and induction of apoptosis were investigated. With concurrent downregulation of the IL-6 receptors, CD130, and CD126, VP79s was found to rapidly reduce both constitutively active and IL-6-induced STAT3 signaling, as well as concurrent downregulation of the IL-6 receptors, CD130, and CD126. Enhanced bortezomib-initiated cell death was discovered in vivo, and it was also found to overcome bone marrow stromal cell resistance induced drug resistance. Significance Assurance is a marketing agent that may have a novel mechanism of action in MM cells as a result of VP79s' rapid inhibition of the key IL-6/STAT3 signaling pathway and downregulation of MCL-1 expression and downregulation with subsequent selective anti-myeloma activity.

Source link: https://europepmc.org/article/MED/34953891

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions